DeutschNewstral
Article
The New York Times on 2022-12-29 19:00
Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen
Related news
- Biogen Abandons Its Controversial Alzheimer’s Drug AduhelmThe New York Times
Biogen plans to shut down its controversial Alzheimer’s drug AduhelmSeattle Times
House investigation faults FDA, Biogen for Alzheimer’s drug approvalpost-gazette.com
Congress faults US regulator’s approval of Biogen Alzheimer’s drugFinancial Times- Biogen Slashes Price of Alzheimer’s Drug Aduhelm, as It Faces ObstaclesThe New York Times
- Congressional Inquiry Into Alzheimer’s Drug Faults Its Maker and F.D.A.The New York Times
Biogen outlines a gloomy forecast due to generics, Aduhelm controversybizjournals.com- FBiogen predicts preventive Alzheimer’s drugft.com
- FFDA approves Biogen Alzheimer’s drugft.com
Will Biogen Stock Come Back Amid Pessimism Surrounding Aduhelm Rollout?Forbes- Change at the top at Biogen after struggles with AduhelmSeattle Times
- Biogen CEO Stepping Down After Struggles With Alzheimer’s Drug AduhelmForbes
Panels find FDA, Biogen rushed Alzheimer’s drugArkansas Online- FBiogen to seek Alzheimer’s drug approvalft.com
Biogen Alzheimer’s Drug Impresses in Early Studywsj.com- BBiogen Sold $1.6M of Aduhelm in Weeks After Approval. Earnings Were Strong.2 min readbarrons.com
- The Petri Dish: Biogen pulls Aduhelm in Europe, medtech startup joins unicorn clubbizjournals.com